Gabapentin
Reading File
Finding Sources
Finding Sources
Searching PubMed
gabapentin clinical pharmacology efficacy safety
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information to provide a detailed answer. Let me compile it.
Gabapentin (Neurontin)
Overview
Gabapentin is a structural analog of GABA (gamma-aminobutyric acid) originally developed as an antispasticity agent, then found to be more useful as an anticonvulsant. It was approved in the United States in 1994 for adjunctive treatment of partial seizures. Its use has since expanded far beyond epilepsy.
Mechanism of Action
Despite its structural similarity to GABA, gabapentin does not act through GABA receptors and has no direct GABAergic activity. Its primary mechanism involves:
- High-affinity binding to α2δ subunits (specifically α2δ-1 and α2δ-2) of voltage-gated calcium channels
- This reduces glutamate release at excitatory synapses (antiglutamatergic effect)
- Inhibits trafficking of presynaptic NMDA receptors to the cell surface, reducing their synaptic incorporation
- Indirectly increases cerebral GABA levels with chronic use
- Also modulates sodium channels and increases whole-blood serotonin concentrations
Notably, gabapentinoids have little direct effect on calcium currents despite binding calcium channel subunits - the calcium channel itself is likely not the primary target.
- Katzung's Basic and Clinical Pharmacology, 16e, p. 654
Formulations & Chemistry
| Formulation | Brand | Notes |
|---|---|---|
| Immediate-release | Neurontin | Capsules (100, 300, 400 mg), tablets (600, 800 mg), oral solution 250 mg/5 mL |
| Sustained-release | Gralise | 300 & 600 mg tablets; taken with evening meal |
| Extended-release prodrug | Horizant (gabapentin enacarbil) | 600 mg; designed for better absorption |
The prodrug gabapentin enacarbil is actively absorbed via high-capacity transporters and has more consistent bioavailability than immediate-release gabapentin. The different formulations are not interchangeable.
Pharmacokinetics
| Parameter | Value |
|---|---|
| Bioavailability | ~60% at 300 mg TID; falls to ~33% at 1200 mg BID (saturable absorption) |
| Peak plasma | 2-3 hours after oral dosing |
| Protein binding | <3% (circulates largely unbound) |
| Volume of distribution | ~1 L/kg |
| Half-life | 5-7 hours (immediate-release); dosed TID for epilepsy |
| Metabolism | Not appreciably metabolized in humans |
| Elimination | Unchanged by renal excretion only |
| Clearance | Correlates directly with creatinine clearance |
| Dialysis | Removed by hemodialysis |
Key kinetic feature: sublinear (saturable) absorption - higher single doses give disproportionately lower bioavailability. Individual doses of immediate-release should not exceed 1,200 mg. Food has modest effects on immediate-release but significantly affects absorption of sustained-release forms.
Dose adjustments required in:
- Renal impairment (reduced clearance)
- Children under 5 years (increased clearance)
- Elderly (decreased clearance)
FDA-Approved Indications
- Partial (focal) seizures - adjunctive treatment in adults and children ≥3 years
- Postherpetic neuralgia - immediate-release, extended-release, and gabapentin enacarbil
- Restless legs syndrome (moderate-to-severe) - gabapentin enacarbil only
Off-Label Uses (with evidence)
- Neuropathic pain (diabetic peripheral neuropathy, others)
- Social anxiety disorder and panic disorder
- Alcohol use disorder / relapse prevention
- Other substance use disorders
- Insomnia (symptom relief)
- Perioperative analgesia (part of multimodal regimens)
Gabapentin is ineffective for acute mania, treatment-resistant bipolar disorder, and generalized (non-focal) epilepsies. It may aggravate absence seizures and myoclonic seizures.
Dosing
| Indication | Starting Dose | Usual Range |
|---|---|---|
| Epilepsy (adults) | 900 mg/day in 3 divided doses | Up to 3600 mg/day (some patients need higher) |
| Postherpetic neuralgia | Lower titration | Individualized |
| Sustained-release (Gralise) | Titrate up | Max 1800 mg once daily with evening meal |
| Gabapentin enacarbil (Horizant) | - | 600 mg once or twice daily |
Adverse Effects
Common (adults, epilepsy):
- Somnolence, dizziness, ataxia, fatigue, nystagmus
Common (postherpetic neuralgia):
- Dizziness, somnolence, peripheral edema
Pediatric patients (3-12 years):
- Viral infection, fever, nausea/vomiting, somnolence, hostility
- Behavioral/psychiatric effects are notable: emotional lability (6%), hostility/aggressiveness (5.2%), hyperkinesia (4.7%)
Serious warnings:
- Suicidality - increased risk (class effect for anticonvulsants)
- Respiratory depression - risk increases with concurrent CNS depressants (opioids, benzodiazepines, especially in elderly or those with COPD)
- Overdose - relatively low toxicity; causes drowsiness, ataxia, nausea, vomiting, resolving in ~10 hours
Pregnancy: Category C (teratogenicity in animals; not confirmed in humans)
Lactation: "Probably safe" - excreted in breast milk (~1 mg/kg/day in nursing infant); use only if benefits outweigh risks
Drug Interactions
Gabapentin has few clinically significant drug-drug interactions because it is not metabolized by hepatic enzymes. Key points:
- Antacids reduce absorption - take gabapentin at least 2 hours after antacids
- Hydrocodone and morphine may increase gabapentin blood concentrations
- CNS depressants (opioids, benzodiazepines, alcohol) have additive sedative/respiratory depression effects - clinically important
Withdrawal
Abrupt discontinuation can cause: anxiety, insomnia, nausea, pain, sweating, headache, convulsions, nervousness, depression, ataxia, dizziness.
Tapering strategy: Due to the hyperbolic dose-effect relationship, linear dose reductions (e.g., 4800 → 3600 → 2400 → 1200 mg) produce increasingly large drops in receptor occupancy at lower doses. To minimize withdrawal severity, doses should be tapered hyperbolically (each step removes a smaller absolute amount). Dosing less than TID (including every-other-day) is not recommended during taper, as the short half-life causes inter-dose withdrawal.
Gabapentin vs. Pregabalin
| Feature | Gabapentin | Pregabalin |
|---|---|---|
| Absorption | Saturable, sublinear | Linear, more predictable |
| Bioavailability | ~60% (dose-dependent) | ~90% (consistent) |
| Half-life | ~6 hours (TID dosing) | Similar |
| Approved for fibromyalgia | No | Yes |
| Approved for generalized anxiety disorder | No | Yes (in some countries) |
| Schedule | Schedule V (US) | Schedule V (US) |
Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Katzung's Basic and Clinical Pharmacology, 16e; The Maudsley Deprescribing Guidelines; Tintinalli's Emergency Medicine; Miller's Anesthesia, 10e
This is a shared conversation. Sign in to Orris to start your own chat.